What is the dosage of Tecentriq?

Tecentriq is available in 2 dosages, including 60 mg/ml Injection 14 ml and 60 mg/ml Injection 20 ml

What does Tecentriq treat?

Tecentriq treats Urinary Bladder Neoplasms and Non-Small-Cell Lung Carcinoma

What is Tecentriq made of?

Tecentriq contains atezolizumab which is a Programmed Death Receptor-1 Blocking Antibody

How is Tecentriq administered?

Tecentriq is administered as a Injectable

What is Tecentriq mechanism of action?

Tecentriq mechanism of action is Programmed Death Receptor-1-directed Antibody Interactions

Dosage & Administration Biomarker testing Drug label Prior authorization Pharmacy Financial assistance

Patient education People also ask

Tecentriq

(atezolizumab)

14 ML atezolizumab 60 MG/ML Injection [Tecentriq]20 ML atezolizumab 60 MG/ML Injection [Tecentriq]

NO BLACK BOX WARNING

Dosage & administration

Administer TECENTRIQ intravenously over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.

Urothelial Carcinoma

* Administer TECENTRIQ as a single agent as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks.

NSCLC

* In the adjuvant setting, administer TECENTRIQ following resection and up to 4 cycles of platinum-based chemotherapy as 840 mg every 2 weeks, 1200 mg every 3 weeks or 1680 mg every 4 weeks for up to 1 year.
* In the metastatic setting, administer TECENTRIQ as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks.
* When administering with chemotherapy with or without bevacizumab, administer TECENTRIQ prior to chemotherapy and bevacizumab when given on the same day.

Small Cell Lung Cancer

* Administer TECENTRIQ as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. When administering with carboplatin and etoposide, administer TECENTRIQ prior to chemotherapy when given on the same day.

Hepatocellular Carcinoma

* Administer TECENTRIQ as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. Administer TECENTRIQ prior to bevacizumab when given on the same day. Bevacizumab is administered at 15 mg/kg every 3 weeks.

Melanoma

* Following completion of a 28 day cycle of cobimetinib and vemurafenib, administer TECENTRIQ 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks with cobimetinib 60 mg orally once daily (21 days on /7 days off) and vemurafenib 720 mg orally twice daily.

biomarker testing

Tecentriq clinical details

Genetic testing requirements were obtained from the NCCN guidelines for each cancer type.

drug label

Tecentriq prescribing information

Contact Medical Science Liaison Report Adverse Event

prior authorization

Tecentriq prior authorization resources

Most recent Tecentriq prior authorization forms

View By Payer

Verified: Sep 28, 2023Cigna - Tecentriq Prior Authorization Form

Verified: Sep 21, 2023Aetna - Tecentriq Prior Authorization Form

Verified: Sep 21, 2023Aetna - Medicare Part B Tecentriq Prior Authorization Form

OTHERComplete Letter of Medical Necessity

OTHERCoverage Authorization Appeals

Learn More

Benefits investigation

PDFCombined Prescriber Service Form and Patient Consent Form

PDFPatient Consent Form - English

PDFPatient Consent Form - Spanish

Prescriber Service Form - Online Portal

Learn More

pharmacy

Tecentriq preferred pharmacy

OTHERPharmacy List

financial assistance

Tecentriq financial assistance options

Co-pay savings program

commercial only

PDFCombined Prescriber Service Form and Patient Consent Form

PDFPatient Consent Form - English

PDFPatient Consent Form - Spanish

Prescriber Service Form - Online Portal

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Foundation programs

under insured

no insurance

goverment insurance

65+

PDFCombined Prescriber Service Form and Patient Consent Form

PDFPatient Consent Form - English

PDFPatient Consent Form - Spanish

Prescriber Service Form - Online Portal

PDFGenentech Patient Foundation Application Form - Prescriber Form

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.